1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Is the shift in treatment patterns toward new, more expensive drugs still driving the increase in pharmaceutical expenditure? : A decomposition analysis of expenditure data in Sweden 1990-2022
2024) In Expert Review of Pharmacoeconomics & Outcomes Research(
- Contribution to journal › Article
- 2021
-
Mark
Elderly individuals with diabetes and foot ulcer have a probability for healing despite extensive comorbidity and dependency
(
- Contribution to journal › Article
- 2018
-
Mark
Social and economic burden of recurrent urinary tract infections and quality of life : a patient web-based study (GESPRIT)
(
- Contribution to journal › Article
- 2017
-
Mark
Transposition and implementation of EU rare disease policy in Eastern Europe
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Advantages and disadvantages of discrete-event simulation for health economic analyses.
2016) In Expert Review of Pharmacoeconomics & Outcomes Research(
- Contribution to journal › Article
-
Mark
Life expectancy and health expenditure evolution in Eastern Europe-DiD and DEA analysis
(
- Contribution to journal › Article
- 2015
-
Mark
Evolution of the Serbian pharmaceutical market alongside socioeconomic transition
(
- Contribution to journal › Article
- 2014
-
Mark
10th World IHEA and ECHE Joint Congress : health economics in the age of longevity
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Contemporary generic market in Japan - key conditions to successful evolution
(
- Contribution to journal › Scientific review
- 2010
-
Mark
Health, happiness, inequality
(
- Contribution to journal › Article